Free Trial
→ Your free book is about to disappear (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$1.61
+0.9%		$1.88
$1.58
▼
$4.94
$91.64M3.48895,530 shs852,374 shs
Celularity, Inc. stock logo
CELU
Celularity
$0.75
+5.6%		$1.23
$0.56
▼
$2.55
$23.07M0.88170,935 shs66,301 shs
Equillium, Inc. stock logo
EQ
Equillium
$1.42
-2.4%		$1.64
$0.76
▼
$3.54
$92.26M2.08463,445 shs215,136 shs
Genelux Corporation stock logo
GNLX
Genelux
$1.88
-3.6%		$2.35
$1.77
▼
$6.26
$88.23M0.68461,551 shs292,380 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-14.25%-11.88%-12.84%-24.05%-63.42%
Celularity, Inc. stock logo
CELU
Celularity
-6.41%-12.98%-54.42%+3.04%-59.83%
Equillium, Inc. stock logo
EQ
Equillium
-3.00%+3.19%+3.19%-33.26%+50.28%
Genelux Corporation stock logo
GNLX
Genelux
-5.80%+1.56%-23.83%-27.78%-66.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$1.61
+0.9%		$1.88
$1.58
▼
$4.94
$91.64M3.48895,530 shs852,374 shs
Celularity, Inc. stock logo
CELU
Celularity
$0.75
+5.6%		$1.23
$0.56
▼
$2.55
$23.07M0.88170,935 shs66,301 shs
Equillium, Inc. stock logo
EQ
Equillium
$1.42
-2.4%		$1.64
$0.76
▼
$3.54
$92.26M2.08463,445 shs215,136 shs
Genelux Corporation stock logo
GNLX
Genelux
$1.88
-3.6%		$2.35
$1.77
▼
$6.26
$88.23M0.68461,551 shs292,380 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-14.25%-11.88%-12.84%-24.05%-63.42%
Celularity, Inc. stock logo
CELU
Celularity
-6.41%-12.98%-54.42%+3.04%-59.83%
Equillium, Inc. stock logo
EQ
Equillium
-3.00%+3.19%+3.19%-33.26%+50.28%
Genelux Corporation stock logo
GNLX
Genelux
-5.80%+1.56%-23.83%-27.78%-66.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
2.60
Moderate Buy$11.00583.23% Upside
Celularity, Inc. stock logo
CELU
Celularity
1.00
SellN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
2.91
Moderate Buy$7.57433.20% Upside
Genelux Corporation stock logo
GNLX
Genelux
2.75
Moderate Buy$20.00963.83% Upside

Current Analyst Ratings Breakdown

Latest CELU, EQ, BDTX, and GNLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/10/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform
10/29/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/26/2026
Equillium, Inc. stock logo
EQ
Equillium
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/15/2026
Genelux Corporation stock logo
GNLX
Genelux
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/12/2026
Equillium, Inc. stock logo
EQ
Equillium
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$6.00
10/9/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/21/2026
Equillium, Inc. stock logo
EQ
Equillium
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/16/2026
Genelux Corporation stock logo
GNLX
Genelux
Lucid Cap Mkts logo
Lucid Cap Mkts
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
9/4/2026
Equillium, Inc. stock logo
EQ
Equillium
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$12.00
8/27/2026
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
8/18/2026
Genelux Corporation stock logo
GNLX
Genelux
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSpeculative Buy
(Data available from 11/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/A$0.53 per share3.03$1.97 per shareN/A
Celularity, Inc. stock logo
CELU
Celularity
$26.55M0.92N/AN/A($1.32) per share-0.57
Equillium, Inc. stock logo
EQ
Equillium
$41.10M2.19N/AN/A$0.47 per share3.02
Genelux Corporation stock logo
GNLX
Genelux
$10K8,505.12N/AN/A$0.30 per share6.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$22.37M-$0.77N/AN/AN/AN/A-35.24%-27.48%N/A
Celularity, Inc. stock logo
CELU
Celularity
-$91.72M-$1.69N/AN/AN/A-246.65%N/A-48.20%11/13/2026 (Estimated)
Equillium, Inc. stock logo
EQ
Equillium
-$22.40M-$0.20N/AN/AN/AN/A-41.15%-38.29%11/12/2026 (Estimated)
Genelux Corporation stock logo
GNLX
Genelux
-$32.15M-$0.86N/AN/AN/AN/A-205.85%-138.79%11/11/2026 (Estimated)

Latest CELU, EQ, BDTX, and GNLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Equillium, Inc. stock logo
EQ
Equillium
-$0.05N/AN/AN/AN/AN/A
11/11/2026Q3 2026
Genelux Corporation stock logo
GNLX
Genelux
-$0.20N/AN/AN/AN/AN/A
11/10/2026Q3 2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-$0.0938-$0.17-$0.0763-$0.17$8.33 millionN/A
10/20/2026Q2 2026
Celularity, Inc. stock logo
CELU
Celularity
N/A$0.02N/A$0.02N/A$5.43 million
9/29/2026Q1 2026
Celularity, Inc. stock logo
CELU
Celularity
N/A$0.02N/A$0.02N/A$3.85 million
8/13/2026Q2 2026
Equillium, Inc. stock logo
EQ
Equillium
-$0.0540-$0.04+$0.0140-$0.04N/AN/A
8/13/2026Q2 2026
Genelux Corporation stock logo
GNLX
Genelux
-$0.1967-$0.21-$0.0133-$0.21N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/AN/AN/AN/A
Celularity, Inc. stock logo
CELU
Celularity
N/AN/AN/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/A
7.28
7.28
Celularity, Inc. stock logo
CELU
Celularity
N/A
0.11
0.10
Equillium, Inc. stock logo
EQ
Equillium
N/A
23.40
23.40
Genelux Corporation stock logo
GNLX
Genelux
N/A
2.39
2.39

Institutional Ownership

CompanyInstitutional Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
95.47%
Celularity, Inc. stock logo
CELU
Celularity
19.02%
Equillium, Inc. stock logo
EQ
Equillium
27.05%
Genelux Corporation stock logo
GNLX
Genelux
37.33%

Insider Ownership

CompanyInsider Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
9.29%
Celularity, Inc. stock logo
CELU
Celularity
17.30%
Equillium, Inc. stock logo
EQ
Equillium
17.84%
Genelux Corporation stock logo
GNLX
Genelux
7.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
2157.45 million52.12 millionOptionable
Celularity, Inc. stock logo
CELU
Celularity
11532.45 million26.84 millionOptionable
Equillium, Inc. stock logo
EQ
Equillium
1463.41 million52.10 millionOptionable
Genelux Corporation stock logo
GNLX
Genelux
2645.24 million41.85 millionOptionable

Recent News About These Companies

Genelux (GNLX) Projected to Release Earnings on Wednesday
October 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-genelux-gnlx-projected-to-release-earnings-on-wednesday-2026-10-28/
Genelux (NASDAQ:GNLX) Raised to Sell at Wall Street Zen
October 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-genelux-nasdaq-gnlx-raised-to-sell-at-wall-street-zen-2026-10-20/
Genelux Corporation (NASDAQ:GNLX) Stock Has Consensus Price Target of $18.00 According to Analysts
October 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-genelux-corporation-nasdaq-gnlx-stock-has-consensus-price-target-of-1800-according-to-analysts-2026-10-14/
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed ...
September 9, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/genelux-announces-publication-of-a-deep-and-durable-response-in-a-platinum-relapsed-small-cell-lung-cancer-patient-following-systemically-delivered-olvi-vec-primed-immunochemotherapy-1036533892
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3359047/0/en/genelux-announces-publication-of-a-deep-and-durable-response-in-a-platinum-relapsed-small-cell-lung-cancer-patient-following-systemically-delivered-olvi-vec-primed-immunochemothera.html
Yong Yu Sells 9,683 Shares of Genelux (NASDAQ:GNLX) Stock
September 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-gnlx-insider-buying-and-selling-2026-09-03/
Genelux Reports Second Quarter 2026 Results and Advances Olvi-Vec Clinical Programs in Ovarian and Lung Cancer
August 13, 2026  |  quiverquant.comQ
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344971/0/en/genelux-corporation-reports-second-quarter-financial-results-and-provides-business-updates.html
Genelux (GNLX) Stock Forecast & Price Target
July 11, 2026  |  investing.comhttps://www.investing.com/equities/genelux-consensus-estimates
Genelux (NASDAQ:GNLX) Director John Smither Sells 12,000 Shares of Stock
July 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-gnlx-insider-buying-and-selling-2026-07-03/
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319590/0/en/genelux-announces-publication-of-translational-analysis-supporting-immune-activation-and-chemotherapy-sensitization-with-olvi-vec-in-ovarian-cancer.html
Genelux Earnings Estimates, EPS & Revenue | NASDAQ:GNLX
June 29, 2026  |  benzinga.comhttps://www.benzinga.com/quote/GNLX/earnings
Insider Selling: Genelux (NASDAQ:GNLX) Director Sells 10,000 Shares of Stock
June 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-gnlx-insider-buying-and-selling-2026-06-03/
Genelux Corporation Common Stock (GNLX)
May 25, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/gnlx/institutional-holdings
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290643/0/en/genelux-corporation-reports-first-quarter-financial-results-and-provides-business-updates.html
Genelux Corporation Common Stock (GNLX) Real-Time
April 7, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/gnlx/real-time
Genelux Establishes $100 Million At-The-Market Equity Program
March 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genelux-establishes-100-million-at-the-market-equity-program?utm_source=marketbeat.com&utm_medium=referral
Genelux Corporation Announces Phase 3 Trial Data Timeline and Interim Results for Olvi-Vec in Ovarian and Lung Cancer, Alongside Leadership Appointment
March 19, 2026  |  quiverquant.comQ
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/19/3259445/0/en/genelux-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates.html
Genelux (NASDAQ:GNLX) Director Sells $29,000.00 in Stock
March 4, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-gnlx-insider-buying-and-selling-2026-03-04/
Genelux Corporation to Participate in Upcoming Conferences
February 18, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/genelux-corporation-to-participate-in-upcoming-conferences-1035840032

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ASML logo on a semiconductor lithography machine with a robotic arm handling silicon wafers in a cleanroom.
ASML Can’t Keep Up With AI Demand—Why That's a Good Thing
By Thomas Hughes | October 15, 2026
Aerial view of an Applied Digital data center facility with cooling units and buildings at sunset.
Powering Up: Applied Digital Execs Buy $6.7M in Stock
By Jeffrey Neal Johnson | October 20, 2026
IonQ logo centered within an illustration of quantum computing hardware featuring glowing orange laser beams.
IonQ's Bold Expansion Could Leave Shareholders Paying the Price
By Nathan Reiff | October 20, 2026
An Uber-branded Tesla SUV parked on a city street with the Uber logo overlaid.
Uber's Profit Drop: A Speed Bump or Structural Shift?
By Jeffrey Neal Johnson | November 5, 2026
Eli Lilly, Moderna, Guardant Health and Illumina Ride AI That Reads the Body
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
By Bridget Bennett | October 19, 2026
Black Diamond Therapeutics stock logo

Black Diamond Therapeutics NASDAQ:BDTX

$1.61 +0.02 (+0.94%)
Closing price 04:00 PM Eastern
Extended Trading
$1.62 +0.00 (+0.31%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Celularity stock logo

Celularity NASDAQ:CELU

$0.75 +0.04 (+5.63%)
Closing price 03:59 PM Eastern
Extended Trading
$0.78 +0.03 (+3.86%)
As of 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Equillium stock logo

Equillium NASDAQ:EQ

$1.42 -0.04 (-2.41%)
Closing price 04:00 PM Eastern
Extended Trading
$1.42 0.00 (0.00%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Genelux stock logo

Genelux NASDAQ:GNLX

$1.88 -0.07 (-3.59%)
Closing price 04:00 PM Eastern
Extended Trading
$1.92 +0.05 (+2.39%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas